Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	883.34M -66.1%
Revenue (ttm)	250.30M +15.5%
Net Income	15.40M
EPS	0.91
Shares Out	16.89M
PE Ratio	57.56
Forward PE	38.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,508
Open	53.70
Previous Close	52.30
Day's Range	51.50 - 53.70
52-Week Range	51.50 - 159.00
Beta	0.78
Analysts	Buy
Price Target	99.24 (+90.85%)
Earnings Date	Nov 3, 2026

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the inter...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2004
• Employees: 110
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2025, Devyser Diagnostics AB's revenue was 250.50 million, an increase of 15.49% compared to the previous year's 216.90 million. Losses were -8.40 million, -86.34% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for DVYSR stock is "Buy." The 12-month stock price target is kr 99.24, which is an increase of 90.85% from the latest price.

Price Target

kr 99.24

(90.85% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error